- Home
- VMET vs AURA Comparison
VMET vs AURA Comparison
Compare VMET & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VMET | AURA |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 956.7M | 797.5M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | VMET | AURA |
|---|---|---|
| Price | $10.27 | $7.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 412.2K | ★ 807.1K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $185.47 | N/A |
| Revenue Next Year | $16.05 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.48 | $4.73 |
| 52 Week High | $13.81 | $9.54 |
Technical Indicators
Market Signals| Indicator | VMET | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 50.87 | 47.58 |
| Support Level | $8.53 | $7.27 |
| Resistance Level | $13.56 | $7.70 |
| Average True Range (ATR) | 0.44 | 0.41 |
| MACD | -0.02 | -0.07 |
| Stochastic Oscillator | 32.43 | 30.01 |
Price Performance
Historical ComparisonAbout VMET Versamet Royalties Corporation Common Stock
Versamet Royalties Corp is a diversified metals royalty and streaming company with exposure to a range of resource royalties and streams including gold, silver, copper, zinc, graphite and uranium, across a variety of jurisdictions. The Company's operating segments are considered to be its individual royalties, streams and the Greenstone gold interest.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.